Polyrizon expands drug delivery innovation with preclinical studies for epilepsy rescue treatment

Raanana, israel, march 25, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the "company" or "polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal benzodiazepines (bzds), a first-line treatment for acute repetitive seizures (ars) and status epilepticus, using its proprietary drug delivery platform.
PLRZ Ratings Summary
PLRZ Quant Ranking